You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: March 29, 2024

Claims for Patent: 9,161,953


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 9,161,953
Title:GLP-1 receptor agonists for islet cell transplantation
Abstract: The disclosure provides methods for treating diabetes by promoting graft survival and improved graft function in a patient receiving an islet transplant by treating the patient with a GLP-1 receptor agonist compound prior to the islet transplant. The methods may also comprise treating the islets with a GLP-1 receptor agonist compound prior to transplanting them in a patient. The methods may eliminate the need for immunosuppressive therapy in islet transplants. Any GLP-1 receptor agonist compound know in the art can be used in the methods described herein.
Inventor(s): Osei; Kwame (San Diego, CA)
Assignee: Amylin Pharmaceuticals, LLC (Wilmington, DE) Eli Lilly And Company (Indianapolis, IN)
Application Number:13/996,093
Patent Claims:1. A method for treating diabetes in a patient in need thereof, the method comprising: (i) administering a therapeutically effective amount of a GLP-1 receptor agonist compound to the patient for a period of time of 1 day to 1 month prior to allogeneic islet transplant; and (ii) transplanting allogeneic islets into the patient; thereby treating the diabetes in the patient, wherein the patient is not administered an immunosuppressive drug or an immunosuppressive treatment regimen before, during, or after any step in the method.

2. The method of claim 1, wherein the patient is a human.

3. The method of claim 1, wherein the GLP-1 receptor agonist compound is an exendin, a GLP-1(7-37), or an analog thereof.

4. The method of claim 1, wherein the GLP-1 receptor agonist compound comprises the amino acid sequence as set forth in SEQ ID NO:1, 3, or 23.

5. The method of claim 1, wherein the GLP-1 receptor agonist compound is exenatide, lixisenatide, liraglutide, dulaglutide, albiglutide, or taspoglutide.

Details for Patent 9,161,953

Applicant Tradename Biologic Ingredient Dosage Form BLA Approval Date Patent No. Expiredate
Glaxosmithkline Llc TANZEUM albiglutide For Injection 125431 04/15/2014 ⤷  Try a Trial 2030-12-22
Eli Lilly And Company TRULICITY dulaglutide Injection 125469 09/18/2014 ⤷  Try a Trial 2030-12-22
Eli Lilly And Company TRULICITY dulaglutide Injection 125469 09/04/2020 ⤷  Try a Trial 2030-12-22
Sanofi-aventis U.s. Llc ADLYXIN lixisenatide Injection 208471 07/27/2016 ⤷  Try a Trial 2030-12-22
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Approval Date >Patent No. >Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.